Liver and Bile

Dig Liver Dis. 2022;54(5):669–75

Sciarrone SS, Ferrarese A, Bizzaro D, Volpato S, Donato FM, Invernizzi F, Trespidi L, Ramezzana IG, Avolio AW, Nure E, Pascale MM, Fagiuoli S, Pasulo L, Merli M, Lapenna L, Toniutto P, Lenci I, Di Donato R, De Maria N, Villa E, Galeota Lanza A, Marenco S, Bhoori S, Mameli L, Cillo U, Boccagni P, Russo FP, Bo P, Cosmi E, Burra P

Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study


Background: Women who have undergone liver transplantation (LT) enjoy better health, and possibility of childbearing. However, maternal and graft risks, optimal immunosuppression, and fetal outcome is still to clarify.
Aim: Aim of the study was to assess outcomes of pregnancy after LT at national level.
Methods: In 2019, under the auspices of the Permanent Transplant Committee of the Italian Association for the Study of the Liver, a multicenter survey including 14 Italian LT-centers was conducted aiming at evaluating the outcomes of recipients and newborns, and graft injury/function parameters during pregnancy in LT-recipients.
Results: 62 pregnancies occurred in 60 LT-recipients between 1990 and 2018. Median age at the time of pregnancy was 31 years and median time from transplantation to conception was 8 years. During pregnancy, 4 recipients experienced maternal complications with hospital admission. Live birth-rate was 100%. Prematurity occurred in 25/62 newborns, and 8/62 newborns had low birth-weight. Cyclosporine was used in 16 and tacrolimus in 37 pregnancies, with no different maternal or newborn outcomes. Low-birth-weight was correlated to high values of aspartate aminotransferase, alanine aminotransferase and gamma glutamyl transferase.

Conclusion: Pregnancy after liver transplantation has good outcome; however, maternal complications and prematurity may occur. Compliance with the immunosuppression is fundamental to ensure the stability of graft function and prevent graft deterioration.

Prof. Dr. P. Burra, Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy,
E-Mail: burra@unipd.it

DOI: DOI: 10.1016/j.dld.2021.08.013

Back to overview

this could be of interest:

Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B Study)

Gastroenterology. 2022;162(3):757–71.e4

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma

J Hepatol. 2022;76(4):862–73

More articles on the topic